Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant

View ORCID ProfileRenato Mendes Coutinho, Flavia Maria Darcie Marquitti, Leonardo Souto Ferreira, Marcelo Eduardo Borges, Rafael Lopes Paixão da Silva, Otavio Canton, Tatiana P. Portella, Silas Poloni, Caroline Franco, Mateusz M. Plucinski, Fernanda C. Lessa, Antônio Augusto Moura da Silva, Roberto Andre Kraenkel, Maria Amélia de Sousa Mascena Veras, Paulo Inácio Prado
doi: https://doi.org/10.1101/2021.03.03.21252706
Renato Mendes Coutinho
aUniversidade Federal do ABC, Santo André, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Renato Mendes Coutinho
  • For correspondence: renato.coutinho@gmail.com
Flavia Maria Darcie Marquitti
bUniversidade Estadual de Campinas, Campinas, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Souto Ferreira
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcelo Eduardo Borges
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Lopes Paixão da Silva
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otavio Canton
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana P. Portella
dUniversidade de São Paulo, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silas Poloni
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Franco
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mateusz M. Plucinski
gCenters for Disease Control and Prevention, Atlanta, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernanda C. Lessa
gCenters for Disease Control and Prevention, Atlanta, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antônio Augusto Moura da Silva
eUniversidade Federal do Maranhão, São Luís, MA, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Andre Kraenkel
cUniversidade Estadual Paulista, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Amélia de Sousa Mascena Veras
fFaculdade de Ciências Médicas da Santa Casa de São Paulo – São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo Inácio Prado
dUniversidade de São Paulo, São Paulo, SP, Brazil
hObservatório COVID-19 BR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The variant of concern (VOC) P.1 emerged in the Amazonas state (Brazil) in November-2020. It contains a constellation of mutations, ten of them in the spike protein. Consequences of these specific mutations at the population level have been little studied so far, despite the detection of P.1 variant in 26 countries, with local transmission in at least four other countries in the Americas and Europe. Here, we estimate P.1’s transmissibility and reinfection using a model-based approach, by fitting data from the Brazilian national health surveillance of hospitalized individuals and frequency of the P.1 variant in Manaus from December 2020 to February 2021, when the city was devastated by four times more cases than in the previous peak (April 2020). The new variant was found to be about 2.6 times more transmissible (95% Confidence Interval (CI): 2.4–2.8) than previous circulating variant(s). The city already had a high prevalence of individuals previously affected by the SARS-CoV-2 virus (estimated as 78%, CI:73–83%), and the fitted model attributed 28% of the cases during the period to reinfections by the variant P.1. Our estimates rank P.1 as the most transmissible among the current identified SARS-CoV-2 VOCs, posing a serious threat and requiring urgent measures to control its global spread.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Ethics approval was not necessary because this study analysed only publicly available data, not including identifiable information.

Funding Statement

This work was supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (Finance Code 001 to FMDM, LSF and TPP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (grant number: 315854/2020-0 to MEB, 141698/2018-7 to RLPS, 313055/2020-3 to PIP, 312559/2020-8 to MASMV, 311832/2017-2 to RAK, 305703/2019-6 to AAMS) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (grant number: 2019/26310-2 and 2017/26770-8 to CF, 2018/26512-1 to OC, 2018/24037-4 to SPL and contract number: 2016/01343-7 to RAK).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was not necessary because this study analysed only publicly available data, not including identifiable information.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • RMC, FMDM, LSF, MEB, RLPS, TPP, SP, CF, RAK, MASMV, and PIP designed research; RMC, FMDM, LSF, MEB, RLPS, TPP, SP, and PIP performed research and analyzed data; and all authors wrote the paper.

Data Availability

All data used are publicly available. The data sources are described in the manuscript and in supplementary file.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 23, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
Renato Mendes Coutinho, Flavia Maria Darcie Marquitti, Leonardo Souto Ferreira, Marcelo Eduardo Borges, Rafael Lopes Paixão da Silva, Otavio Canton, Tatiana P. Portella, Silas Poloni, Caroline Franco, Mateusz M. Plucinski, Fernanda C. Lessa, Antônio Augusto Moura da Silva, Roberto Andre Kraenkel, Maria Amélia de Sousa Mascena Veras, Paulo Inácio Prado
medRxiv 2021.03.03.21252706; doi: https://doi.org/10.1101/2021.03.03.21252706
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
Renato Mendes Coutinho, Flavia Maria Darcie Marquitti, Leonardo Souto Ferreira, Marcelo Eduardo Borges, Rafael Lopes Paixão da Silva, Otavio Canton, Tatiana P. Portella, Silas Poloni, Caroline Franco, Mateusz M. Plucinski, Fernanda C. Lessa, Antônio Augusto Moura da Silva, Roberto Andre Kraenkel, Maria Amélia de Sousa Mascena Veras, Paulo Inácio Prado
medRxiv 2021.03.03.21252706; doi: https://doi.org/10.1101/2021.03.03.21252706

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)